Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Anastrozole Stories

2008-08-27 12:00:27

SCOTTSDALE, Ariz., Aug. 27 /PRNewswire/ -- MedPredict has published a new report in its oncology series entitled "Thought Leader Insight & Analysis: Breast Cancer," designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area. MedPredict interviewed renowned North American and European breast cancer thought leaders to identify the most promising candidates in clinical development, as well...

2008-07-18 12:00:26

Meditrina Pharmaceuticals has announced the approval of its second investigational new drug application for a Phase IIb dose ranging clinical trial to study MPI-676, the company's aromatase inhibitor, in combination with estrogen and progestin for the treatment of endometriosis. This US-based, multi-center, placebo-controlled, double-blinded study will identify the maximally efficacious dose of MPI-676 to investigate in the pivotal Phase III program. The Phase IIb dose ranging trial will...

2008-07-17 09:00:19

ANN ARBOR, Mich., July 17 /PRNewswire/ -- Meditrina Pharmaceuticals, Inc. today announced the approval of its second investigational new drug (IND) application for a Phase IIb dose ranging clinical trial to study MPI-676, the Company's aromatase inhibitor (AI), in combination with estrogen and progestin for the treatment of endometriosis. MPI-676 is the newest addition to Meditrina's clinical stage product portfolio that currently includes Femathina(TM) (MPI-674), an AI that Meditrina is...

2008-06-30 15:02:00

By RANKIN, Janine -------------------- Palmerston North women at high risk of developing breast cancer are being sought to take part in a huge international trial for a promising prevention, but there's a catch. MidCentral Health is not one of the four New Zealand centres involved in the IBIS II study, so women would have to make six visits over five years at their own expense to Waikato or Wellington to find out whether the drug anastrozole works. The New Zealand Breast Cancer...

7f45ffaa441f0c3e7683ba96796e754b
2008-06-02 15:29:29

In the first large study to affirm wider cancer-fighting applications for Zometa and other bone-building drugs called bisphosphonates, new research has found that Zometa, a bone loss prevention drug used by women undergoing breast cancer treatment, substantially reduced the risk of breast cancer recurrence.  The study, led by Dr. Michael Gnant of the Medical University of Vienna, was  reported Saturday at an American Society of Clinical Oncology conference in Chicago, and has given...

2006-08-11 02:08:03

LONDON (Reuters) - Britain's cost-effectiveness watchdog NICE came one step closer on Friday to approving a new class of breast cancer treatments known as aromatase inhibitors. The decision by the National Institute of Health and Clinical Excellence (NICE) to proceed to its final appraisal means drugs made by the likes of AstraZeneca, Swiss drugmaker Norvatis and Pfizer Inc. could soon be freely available to patients on the country's National Health Service. NICE said its appraisals...

2006-08-02 18:26:18

By Anthony J. Brown, MD NEW YORK (Reuters Health) - As add-on therapy for early-stage breast cancer, the drug anastrozole, known by the brand name Arimidex, is less likely than tamoxifen to cause adverse effects, including serious events and those leading to treatment discontinuation, new research suggests. In 2005, the results of the "Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial were published and showed a benefit for Arimidex over tamoxifen in terms of disease-free...

2006-06-04 12:06:49

By Lisa Richwine ATLANTA (Reuters) - Switching to Pfizer Inc.'s drug Aromasin after a few years on another breast cancer treatment cut some women's risk of dying from the disease by 17 percent in a study released on Saturday. Researchers looked at more than 4,700 women past menopause who had been treated for early stage breast cancer and were disease-free after two to three years of taking the drug tamoxifen to prevent a recurrence. About half were randomly chosen to substitute...

2006-06-03 15:28:25

By Lisa Richwine ATLANTA (Reuters) - Switching to Pfizer Inc.'s drug Aromasin after a few years on another breast cancer treatment cut some women's risk of dying from the disease by 17 percent in a study released on Saturday. Researchers looked at more than 4,700 women past menopause who had been treated for early stage breast cancer and were disease-free after two to three years of taking the drug tamoxifen to prevent a recurrence. About half were randomly chosen to substitute...

2006-05-29 07:42:21

ZURICH (Reuters) - Roche on Monday unveiled new data showing that its cancer drug Herceptin increased the time that some breast-cancer patients live without the cancer progressing when used in combination with hormonal therapy. The Swiss pharmaceutical group Roche said the late-stage, or Phase III, trial results were for patients whose advanced breast cancer was hormone receptor-positive, as well as HER2-positive, a particularly aggressive form of the disease. Hormone...